Sofinnova Partners Appoints Mary McCarthy as Partner for the Firm’s Industrial Biotech Strategy
20.4.2023 11:00:00 EEST | Business Wire | Press release
Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team. She will use her extensive experience and network to help identify the most promising early-stage companies developing biotech-enabled sustainable solutions in agriculture, food, chemicals, and materials. The Sofinnova Industrial Biotech Strategy has made 24 investments to date and is actively investing out of its third fund of €175M.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005098/en/
Mary McCarthy (Photo: Business Wire)
Before joining Sofinnova Partners, Mary was a Partner at Brightlands Venture Partners (BVP) where she was the Fund Manager of the BVP Renewable Chemistry Fund and served on various boards. With over 24 years in chemistry and materials, Mary has occupied various roles in the sector: She was CEO of a start-up developing materials for the circular economy and worked at SABIC for 15 years, where she held various functions in R&D, HR, Change Management, and Corporate Venturing.
Michael Krel, Partner at Sofinnova Partners, said: "Mary is a perfect addition to our team with broad experience in the venture, start-up and corporate world. This appointment is another step forward in the growth of our industrial biotech strategy; it bolsters our commitment to identifying and supporting early-stage companies that have the potential to develop innovations with strong environmental impact."
Joško Bobanović, Partner at Sofinnova Partners, said: "Mary joins our team at an exciting time of growth and evolution of the industrial biotech ecosystem. With her track record of successful investments, Mary will strengthen our capacity to meet the increasing demand for innovative and sustainable solutions for the environment."
Mary McCarthy, Partner at Sofinnova Partners, said: "I'm very pleased to join Sofinnova Partners. The Industrial Biotech team is a recognized pioneer in the sector with a wealth of accumulated knowledge. I am looking forward to contributing to the team’s mission of finding deeptech solutions with strong environmental impact that can truly change the world for the better."
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: "Mary’s appointment strengthens Sofinnova’s leadership position in industrial biotech and reinforces the work this team has been doing for over a decade in forging a strong platform through investments in sustainability. Industrial biotech is a crucial pillar for the future of our firm, and Mary’s extensive network, ability to recognize disruptive technology, and genuine commitment to make the global economy more sustainable will undoubtedly contribute to accelerating this trajectory."
Mary holds a PhD in chemistry from University College Dublin, Ireland and held postdoctoral fellowships at the University of Amsterdam, the Netherlands and the Max Planck Institute für Kohlenforschung, Germany.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005098/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
United Kingdom
Optimum Strategic Communications
Hollie Vile
sofinnova@optimumcomms.com
+44 (0) 20 3922 0900
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavaraiext@havaspr.com
+39 (0) 392 77 999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smiths Detection Celebrates Sale of its 2,000 th HI-SCAN 6040 CTiX 3D X-ray Scanner12.3.2026 11:00:00 EET | Press release
Smiths Detection, a global leader in threat detection and screening solutions, today announces the sale of its 2,000th HI-SCAN 6040 CTiX, an industry-leading 3D X-ray scanner with high-resolution 3D computed tomography images and intelligent AI-driven automatic detection capabilities. The HI-SCAN 6040 CTiX is deployed across over 100 airports in Europe, Asia-Pacific, the Middle East and the Americas. Operational experience across these regions has demonstrated consistent benefits for airports and passengers alike. Fewer false alarms mean faster, more reliable screening, and as threat profiles change, the technology keeps pace, strengthening security resilience over time. Meanwhile, in eligible locations, passengers no longer need to remove laptops or liquids from their bags, a small change that has a real impact on congestion at security checkpoints. Matt Clark, VP Commercial at Smiths Detection, said: “The sale of our 2,000th HI-SCAN 6040 CTiX is a powerful endorsement of the trust ai
COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 10:00:00 EET | Press release
The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using optical “masking” that reduces the visual appearance of moisture, helping to make sweat marks less noticeable. Because the technology is built into the durable
Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 10:00:00 EET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav
EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 10:00:00 EET | Press release
EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the need for responsible, trusted AI in safety. 2025 momentum that mirrors the mega trends In 2025, EcoOnline saw these market shifts reflected in customer usage, adoption, and product expansi
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom